Jun 10, 2021 / 08:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Vertex Pharmaceuticals VX-864 Phase II Results Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Michael Partridge. Please go ahead. .
Michael Partridge - Vertex Pharmaceuticals Incorporated - SVP of IR
Thank you. Good afternoon. This is Michael Partridge of Vertex. On today's call, we will discuss results from the Phase II clinical study with our investigational Z-AAT corrector, VX-864, for the treatment of alpha-1 antitrypsin deficiency or AATD. Dr. Reshma Kewalramani, Vertex' CEO and President, will provide prepared remarks on the call today. Dr. David Altshuler, Vertex' Head of Global Research and Chief Scientific Officer, will join for Q&A. We expect today's call to run for approximately 30 minutes, and we intend to conclude the call at 5 p.m.
We recommend that you access the webcast slides as you listen to this call. This call is being recorded. A replay will be available on the Vertex website.
We will make forward
Vertex Pharmaceuticals Inc to Discuss VX-864 Phase 2 Results and Alpha-1-Antitrypsin Deficiency (AATD) Program Update Call Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers